(Q33342696)

26 July 2017

title

Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

D Pectasides

1

1 reference

26 July 2017

A Visvikis

2

1 reference

26 July 2017

A Kouloubinis

3

1 reference

26 July 2017

J Glotsos

4

1 reference

26 July 2017

N Bountouroglou

5

1 reference

26 July 2017

N Karvounis

6

1 reference

26 July 2017

N Ziras

7

1 reference

26 July 2017

A Athanassiou

8

1 reference

26 July 2017

publication date

1 June 2002

1 reference

European Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

38

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1194-1200

1 reference

26 July 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

1 reference

7 January 2021

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900027-8

7 January 2021

10.1016/S0959-8049(02)00027-8

Identifiers

DOI

1 reference

release_rbkzljdfi5c3boldfd3fmnxwv4

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rbkzljdfi5c3boldfd3fmnxwv4

24 November 2022

mapped directly with Wikidata item

1 reference